The Challenge With Gravity
Many of today's most advanced drugs, from cancer therapies to treatments for rare genetic disorders, are based on proteins. To design these drugs effectively, scientists need a perfectly clear, three-dimensional model of a target protein's structure.
The gold standard for getting this model is a process called X-ray crystallography, which requires growing a highly pure and well-ordered protein crystal. However, growing these perfect crystals on Earth is incredibly difficult. The force of gravity causes two major problems: convection and sedimentation. As crystals form in a solution, they create density changes that cause the fluid to move, disrupting the delicate process of molecules aligning into a perfect lattice. Furthermore, gravity pulls the heavier, growing crystals down, causing them to settle unevenly and develop defects. These imperfections can make the resulting crystal useless for detailed analysis.
A Perfect Crystal in Zero-G
In the microgravity environment of low-Earth orbit, these problems vanish. With gravity's influence drastically reduced, the convection currents that disrupt crystal growth on Earth do not form. Molecules in the solution move only through slow, gentle diffusion, allowing them to settle into the crystal lattice in a much more orderly and deliberate fashion. This stable environment allows for the growth of larger, more uniform, and structurally superior crystals. Research conducted on the International Space Station (ISS) has repeatedly shown that crystals grown in space are often of a higher quality than their terrestrial counterparts. This superior quality allows for more precise structural analysis, giving scientists the high-resolution data they need to design more effective drugs with fewer side effects.
Beyond the ISS: The Rise of Commercial Platforms
For decades, this valuable research was confined to government-run assets like the Space Shuttle and the ISS. While groundbreaking, access was limited and expensive. Today, the landscape is rapidly changing with the rise of the commercial space industry. Companies like Varda Space Industries, Axiom Space, and others are developing their own orbital platforms, from small, uncrewed capsules to full-fledged commercial space stations. These platforms are designed specifically for in-space research and manufacturing. This commercial shift is making access to microgravity more frequent, more affordable, and more predictable. Instead of waiting years for a spot on a government mission, pharmaceutical companies can now partner with these private firms to conduct experiments on a more regular cadence.
The Business of Space-Based Pharmaceuticals
The implications of this new era are enormous. The global space-based biopharmaceuticals market was valued at approximately $1.8 billion in 2025 and is projected to grow significantly. Major pharmaceutical players like Merck and Bristol Myers Squibb have already conducted successful experiments in space. For example, Merck's work on its cancer drug Keytruda showed that microgravity experiments could lead to new formulations that are easier for patients to take. Startups are also getting in on the action. Varda Space Industries has successfully launched multiple missions to crystallize drugs like ritonavir in orbit, proving the viability of autonomous, uncrewed space factories. Another company, LambdaVision, is using microgravity to produce higher-quality artificial retinas made from protein layers, which could one day treat blindness.
From Lab to Orbit to Pharmacy
The ultimate vision is not just to conduct research in space, but to manufacture there as well. For certain high-value, difficult-to-make therapeutics, orbital factories could become a critical part of the supply chain. These commercial platforms offer a path to scale up production beyond what's possible on the research-focused ISS. As companies refine their processes, they are building the foundation for a future where space-made materials become commonplace in medicine. While full-scale orbital drug manufacturing may still be a few years away, the path is being paved now. The ability to create purer protein crystals is crucial, not just for understanding diseases, but for creating the next generation of targeted, life-saving medicines. This makes commercial space platforms an indispensable tool for the future of the pharmaceutical industry.
